Safety and efficacy of AMG 334 for prevention of episodic migraine: A randomised, double-blind, placebo-controlled, phase 2 trial

The Lancet Neurology

Volumn 15, Issue 4, 2016, Pages 382-390

  Sun, Hong ^a   Dodick, David W ^b   Silberstein, Stephen ^c   Goadsby, Peter J ^d   Reuter, Uwe ^e   Ashina, Messoud ^f   Saper, Joel ^g   Cady, Roger ^h   Chon, Yun ^a   Dietrich, Julie ^a   Lenz, Robert ^a  

^a AMGEN INC   (United States)

^b MAYO CLINIC   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f UNIVERSITY OF COPENHAGEN   (Denmark)

^g Michigan Head Pain and Neurological Institute   (United States)

^h HEADACHE CARE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMG 334; ASPARTATE AMINOTRANSFERASE; CALCITONIN GENE RELATED PEPTIDE RECEPTOR; HUMAN MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PLACEBO; UNCLASSIFIED DRUG; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ADULT; ANTIBODY PRODUCTION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EPISODIC MIGRAINE; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HUMAN; MALE; MULTICENTER STUDY; OPEN STUDY; OVARY CYST; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; TREATMENT OUTCOME; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; MIDDLE AGED; MIGRAINE DISORDERS; OUTCOME ASSESSMENT;

ADULT; ANTIBODIES, MONOCLONAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; OUTCOME ASSESSMENT (HEALTH CARE); RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE;

EID: 84960476959     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(16)00019-3     Document Type: Article

References (40)

1. Hepp Z, Bloudek LM, Varon SF Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm 2014, 20:22-33.
2. Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007, 68:343-349.
3. Goadsby PJ, Edvinsson L, Ekman R Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990, 28:183-187.
4. Goadsby PJ, Edvinsson L The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993, 33:48-56.
5. Hansen JM, Hauge AW, Olesen J, Ashina M Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia 2010, 30:1179-1186.
6. Edvinnson L Functional role of perivascular peptides in the control of cerebral circulation. Trends Neurosci 1985, 8:126-131.
7. Olesen J, Diener HC, Husstedt IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004, 350:1104-1110.
8. Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 2008, 372:2115-2123.
9. Hewitt DJ, Aurora SK, Dodick DW, et al. Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia 2011, 31:712-722.
10. Marcus R, Goadsby PJ, Dodick D, Stock D, Manos G, Fischer TZ BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia 2014, 34:114-125.
11. Diener HC, Barbanti P, Dahlof C, Reuter U, Habeck J, Podhorna J BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia 2011, 31:573-584.
12. Ho TW, Connor KM, Zhang Y, et al. Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. Neurology 2014, 83:958-966.
13. Bigal ME, Dodick DW, Rapoport AM, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol 2015, 14:1081-1090.
14. Bigal ME, Edvinsson L, Rapoport AM, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol 2015, 14:1091-1100.
15. Dodick DW, Goadsby PJ, Silberstein SD, et al. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol 2014, 13:1100-1107.
16. Dodick DW, Goadsby PJ, Spierings EL, Scherer JC, Sweeney SP, Grayzel DS Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol 2014, 13:885-892.
17. Shi L, Lehto SG, Zhu DX, et al. Pharmacological characterization of AMG 334, a potent and selective human monoclonal antibody against the calcitonin gene-related peptide (CGRP) receptor. J Pharmacol Exp Ther 2016, 356:223-231.
18. de Hoon JN, Van Hecken A, Yan L, et al. Single-dose and multiple dose, phase 1, randomized, double-blind, placebo-controlled studies of AMG 334 in healthy subjects and migraine patients. Headache 2015, 55(suppl S3):174-175.
19. Vu T, Ma P, Chen J, et al. Characterizing the relationship between AMG 334 concentration and capsaicin-induced increase in dermal blood flow in healthy subjects and migraine patients using pharmacokinetic-pharmacodynamic modeling. Headache 2015, 55(suppl S3):175-176.
20. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004, 24(suppl 1):9-160. Headache Classification Subcommittee of the International Headache Society.
21. Brandes JL, Saper JR, Diamond M, et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA 2004, 291:965-973.
22. Freitag FG, Collins SD, Carlson HA, et al. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology 2002, 58:1652-1659.
23. Eftekhari S, Gaspar RC, Roberts R, et al. Localization of CGRP receptor components and receptor binding sites in rhesus monkey brainstem: a detailed study using in situ hybridization, immunofluorescence, and autoradiography. J Comp Neurol 2016, 524:90-118.
24. Edvinsson L CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment. Br J Clin Pharmacol 2015, 80:193-199.
25. Eftekhari S, Salvatore CA, Johansson S, Chen TB, Zeng Z, Edvinsson L Localization of CGRP, CGRP receptor, PACAP and glutamate in trigeminal ganglion. Relation to the blood-brain barrier. Brain Res 2015, 1600:93-109.
26. Dreier JP, Jurkat-Rott K, Petzold GC, et al. Opening of the blood-brain barrier preceding cortical edema in a severe attack of FHM type II. Neurology 2005, 64:2145-2147.
27. DosSantos MF, Holanda-Afonso RC, Lima RL, DaSilva AF, Moura-Neto V The role of the blood-brain barrier in the development and treatment of migraine and other pain disorders. Front Cell Neurosci 2014, 8:302.
28. Edvinsson L, Tfelt-Hansen P The blood-brain barrier in migraine treatment. Cephalalgia 2008, 28:1245-1258.
29. Vermeersch SGG, de Hoon J, De Saint-Hubert B, et al. PET imaging in healthy subjects and migraineurs suggests CGRP receptor antagonists do not have to act centrally to achieve clinical efficacy. J Headache Pain 2013, 14:P224.
30. Hostetler ED, Joshi AD, Sanabria-Bohorquez S, et al. In vivo quantification of calcitonin gene-related peptide receptor occupancy by telcagepant in rhesus monkey and human brain using the positron emission tomography tracer [11C]MK-4232. J Pharmacol Exp Ther 2013, 347:478-486.
31. Walker CS, Eftekhari S, Bower RL, et al. A second trigeminal CGRP receptor: function and expression of the AMY1 receptor. Ann Clin Transl Neurol 2015, 2:595-608.
32. Walker CS, Hay DL CGRP in the trigeminovascular system: a role for CGRP, adrenomedullin and amylin receptors?. Br J Pharmacol 2013, 170:1293-1307.
33. Sun H, Gavva N, Xu C Inhibitors of CGRP function differentially affect calcitonin-family ligand/receptor interactions. Headache 2015, 55(suppl S5):252.
34. Vécsei L, Majláth Z, Szok D, Csáti A, Tajti J Drug safety and tolerability in prophylactic migraine treatment. Expert Opin Drug Saf 2015, 14:667-681.
35. Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia 2015, 35:478-488.
36. Silberstein SD, Neto W, Schmitt J, Jacobs D Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol 2004, 61:490-495. MIGR-001 Study Group.
37. Goadsby PJ, Dodick D, Martinez J, et al. Onset of efficacy of LY2951742 in migraine prevention: post-hoc analysis of phase 2a, randomized, double-blind, placebo-controlled study data of a calcitonin gene-related peptide monoclonal antibody. Cephalalgia 2015, 35:55.
38. Russell FA, King R, Smillie SJ, Kodji X, Brain SD Calcitonin gene-related peptide: physiology and pathophysiology. Physiol Rev 2014, 94:1099-1142.
39. Bigal ME, Walter S, Bronson M, Alibhoy A, Escandon R Cardiovascular and hemodynamic parameters in women following prolonged CGRP inhibition using LBR-101, a monoclonal antibody against CGRP. Cephalalgia 2014, 34:968-976.
40. Chaitman BR, Ho AP, Behm MO, et al. A randomized, placebo-controlled study of the effects of telcagepant on exercise time in patients with stable angina. Clin Pharmacol Ther 2012, 91:459-466.